Matthias Aizenberg

Matthias Aizenberg

Healthcare Innovation Consultant
Matthias Aizenberg is a seasoned expert in the Healthcare industry. He explores digital health, clinical processes, and healthcare management strategies. Matthias has a deep interest in pharmaceutical and healthcare innovation and is a well-trusted resource for biopharma professionals.
Benitec Biopharma's Stock Soars Amidst Growing Cash Burn Concerns
Management & Regulatory Benitec Biopharma's Stock Soars Amidst Growing Cash Burn Concerns

Benitec Biopharma (NASDAQ:BNTC) has recently captured the attention of investors with a monumental surge in its stock price, boasting a remarkable 205% increase over the past year. This surge is particularly striking given that Benitec, a biotechnology firm focusing on gene therapy, has yet to

Avantor and NIBRT Partner to Boost Biopharma mAbs Manufacturing Efficiency
Biotech & Bioprocessing Avantor and NIBRT Partner to Boost Biopharma mAbs Manufacturing Efficiency

The biopharmaceutical industry has seen significant advancements, particularly in the production of monoclonal antibodies (mAbs), which offer personalized therapies for a range of chronic and debilitating conditions. Despite these advancements, manufacturers face growing pressure to expedite the

How Does Additive Manufacturing Meet Biopharma's Sustainability Goals?
Management & Regulatory How Does Additive Manufacturing Meet Biopharma's Sustainability Goals?

Additive manufacturing, commonly known as 3D printing, has emerged as a revolutionary technology within the biopharmaceutical industry, offering considerable benefits. One of the most compelling advantages of additive manufacturing is its potential to optimize cleanroom space through the

Is PureTech's Hub-and-Spoke Model Misunderstood by Investors?
Management & Regulatory Is PureTech's Hub-and-Spoke Model Misunderstood by Investors?

PureTech Health, a Boston-based biotechnology firm, employs an innovative "hub-and-spoke" model, centralizing resources and expertise to support various offshoot companies focused on specific therapeutic areas or drug-making technologies. This approach aims to merge the strengths of a centralized

CVS Health Replaces CEO Amid Financial Strain and Strategic Shifts
Management & Regulatory CVS Health Replaces CEO Amid Financial Strain and Strategic Shifts

In a surprising move to address ongoing financial difficulties and strategic challenges, CVS Health has made a significant leadership change by replacing CEO Karen Lynch with David Joyner, head of Caremark. This transition underscores the pressing need for CVS to stabilize its operations and refine

Can Novartis and Baiyu Revolutionize Cancer Treatment Together?
Research & Development Can Novartis and Baiyu Revolutionize Cancer Treatment Together?

In a bold move that underscores its commitment to advancing cancer therapies, Novartis has taken a significant step by investing $70 million upfront in Chengdu Baiyu Pharmaceutical for global rights to a small molecule cancer treatment. This partnership is accompanied by potential milestone

Quantum BioPharma Expands with Unbuzzd Launch in Global Markets
Management & Regulatory Quantum BioPharma Expands with Unbuzzd Launch in Global Markets

Quantum BioPharma Ltd. (NASDAQ: QNTM) is making strategic moves to enhance its presence in the health and wellness sector through its subsidiary, Celly Nutrition Corp. Celly Nutrition has clinched a Master Distribution Agreement with FUSION Consulting Group for its innovative product, Unbuzzd.

How Does Proper COA Selection Influence Drug Development Success?
Research & Development How Does Proper COA Selection Influence Drug Development Success?

Clinical Outcome Assessments (COAs) play a pivotal role in the drug development process. These tools, which measure the impact of a treatment on patients' health status, encompass several types: Patient-Reported Outcomes (PROs), Clinician-Reported Outcomes (ClinROs), Observer-Reported Outcomes

Catalent Sells N.J. Facility to Ardena Amid Expansion and Acquisition Plans
Management & Regulatory Catalent Sells N.J. Facility to Ardena Amid Expansion and Acquisition Plans

Catalent, a prominent contract development and manufacturing organization (CDMO), has announced the divestment of its Somerset, New Jersey, oral solids development and small-scale manufacturing facility to Ardena, a Belgian CDMO. This transaction marks Ardena's entry into the U.S. market and

How Will the Biosecure Act and AI Shape Pharma's Future Automation?
Biotech & Bioprocessing How Will the Biosecure Act and AI Shape Pharma's Future Automation?

The pharmaceutical industry is on the cusp of transformative changes over the next decade. Driven by new legislation and technological advancements, companies are rethinking traditional practices. The Biosecure Act, soon to be enacted in the US, and the rise of AI and automation, are key drivers of

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later